Nucleoside and nucleobase analogs in cancer treatment: Not only sapacitabine, but also gemcitabine

Expert Opinion on Investigational Drugs

Volumn 21, Issue 4, 2012, Pages 403-408

  Muggia, Franco ^a   Diaz, Isabela ^b   Peters, Godefridus J ^c  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL DE GALDAKAO   (Spain)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Nucleoside; Nucleoside base analogs; Sapacitabine

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEOXYCYTIDINE PHOSPHATE DEAMINASE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; HYDROXYUREA; NUCLEIC ACID BASE; NUCLEOSIDE DERIVATIVE; PACLITAXEL; PLATINUM DERIVATIVE; RIBONUCLEOTIDE REDUCTASE; SAPACITABINE; THYMIDYLATE SYNTHASE; TRABECTEDIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; DRUG INFORMATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; ENZYME INHIBITION; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; PANCREAS CANCER; REVIEW;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOSIDES; CYTOSINE; DEOXYCYTIDINE; HUMANS; NEOPLASMS; NUCLEOSIDES;

EID: 84858246736     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.666236     Document Type: Review

References (44)

1. Adema AD, Bijnsdorp IV, Sandvold ML, et al. Innovations and opportunities to improve conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer. Curr Med Chem 2009;16:4632-43
2. Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 2003;8:553-66 (Pubitemid 37467371)
3. Peters GJ, Backus HHJ, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002;1587:194-205 (Pubitemid 34655788)
4. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002;5:19-33
5. Adema AD, Losekoot N, Smid K, et al. Differential metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Invest New Drugs 2011; In press
6. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024-31
7. Heinemann V, Xu YZ, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol Pharmacol 1990;38:567-72 (Pubitemid 20356209)
8. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998;58:4349-57 (Pubitemid 28450036)
9. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. Cancer Res 1992;52:533-9
10. Ruiz van Haperen V, Veerman G, Vermorken JB, Peters GJ. 2',2'-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 1993;46:762-6 (Pubitemid 23262974)
11. Ruiz van Haperen VW, Veerman G, Boven E, et al. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 1994;48:1327-39
12. Honeywell R, Giovannetti E, Peters GJ. Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS. Nucleosides Nucleotides Nucleic Acids 2011;30:1203-13
13. Huang P, Chubb S, Hertel LW, et al. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-17
14. Peters GJ, Van Moorsel CJ, Lakerveld B, et al. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or-resistant human ovarian cancer cell lines. Int J Oncol 2006;28:237-44
15. Pauwels B, Korst AE, Lardon F, Vermorken JB. Combined modality therapy of gemcitabine and radiation. Oncologist 2005;10:34-51 (Pubitemid 40171250)
16. Tempero M, Plunkett W, Ruiz van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402-8 (Pubitemid 46594072)
17. Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008; 109(3):329-34 (Pubitemid 351754961)
18. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:3778-85
19. Grimison P, Galletis P, Manners S, et al. Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of auto-induction of gemcitabine accumulation. J Clin Oncol 2007;36:5704-9
20. De Lange SM, Van der Born K, Kroep JR, et al. No evidence of gemcitabine accumulation during weekly administration. Eur J Clin Pharmacol 2005;61:843-9 (Pubitemid 41720273)
21. Veerman G, Ruiz van Haperen VWT, Vermorken JB, et al. Antitumor activity of prolonged as compared with bolus administration of 2',2'- difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996;38:335-42
22. van Riel JM, Peters GJ, Mammatas LH, et al. A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. Eur J Cancer 2009;45:2519-27
23. Witjes JA, Van der Heijden AG, Vriesema JLJ, et al. Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 2004;45:182-6 (Pubitemid 38152999)
24. Morgan RJ Jr, Synold TW, Xi B, et al. Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res 2007;13:1232-7 (Pubitemid 46437052)
25. Sabbatini P, Aghajanian C, Leitao M, et al. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II trial. Clin Cancer Res 2004;10:2962-7 (Pubitemid 38619671)
26. Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacological aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010;70:4528-38
27. Voortman J, Goto A, Mendiboure J, et al. Small cell lung carcinoma-resection of non treated with adjuvant chemotherapy after complete MicroRNA. Cancer Res 2010;70:8288-98
28. Ciccolini J, Mercier C, Dahan L, Andre N. Integrating pharmacogenetics into gemcitabine dosing-time for a change? Nat Rev Clin Oncol 2011;8:439-44
29. Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011;29:abstract LBA5007
30. Bolis G, Scarfone G, Giardina G, et al. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin-or carboplatin- sensitive ovarian cancer. Gynecol Oncol 2001;81:3-9 (Pubitemid 32368070)
31. Cantu MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002;20(5):1232-7 (Pubitemid 34177429)
32. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24(29):4699-707 (Pubitemid 46630933)
33. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361(9375):2099-106
34. Pujade-Lauraine E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28(20):3323-9
35. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28(19):3107-14
36. van Moorsel CJ, Kroep JR, Pinedo HM, et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 1999;10:441-8 (Pubitemid 29236422)
37. Nagourney RA, Brewer CA, Radecki S, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 2003;88(1):35-9 (Pubitemid 36067331)
38. Bergman AM, Kuiper CM, Voorn DA, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 2004;67:503-11 (Pubitemid 38232890)
39. Rizzieri D, Vey N, Schlenck N, et al. A phase II study of elacytarabine/idarubicin as second course remission-induction in patients with acute myeloid leukemia who failed cytarabine/anthracycline, and evaluation of the impact of the nucleoside transporter hENT1 on response. Blood Proc ASH 2011;abstract #42825
40. Sigmond J, Kamphuis JA, Laan AC, et al. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. Biochem Pharmacol 2007;73:1548-57 (Pubitemid 46527545)
41. Yen Y, Chow W, Leong L, et al. Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. Cancer Chemother Pharmacol 2002;50(5):353-9 (Pubitemid 35440523)
42. Traynor AM, Lee JW, Bayer GK, et al. A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: eastern Cooperative Oncology Group Study 1503. Invest New Drugs 2010;28:91-7
43. Muggia FM, Hazarika M. Ovarian cancer: rationale and strategies beyond first-line treatment. In: Angioli R, Kavanagh JJ, Pecorelli S, Penalver M, editors. Chemotherapy for Gynecological Neoplasms: Current Therapy and Novel Approaches. Marcel Dekker; New York: 2004. p. 471-82
44. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-kappaB and Akt/P13K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22:3243-51 (Pubitemid 36712936)